Bristol Myers Squibb Highlights Opdivo Regime Data In Lung Cancer Settings

Bristol Myers Squibb & Co BMY announced the first disclosure of data from the Phase 3 CheckMate -77T trial of the perioperative regimen of neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo in patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC)

With a median follow-up of 25.4 months, in patients treated with the Opdivo regime, the risk of disease recurrence, progression or death was reduced by 42%, compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo.

Also Read: Bristol Myers Squibb Strengthens Oncology Portfolio With Mirati Therapeutics' $5B Deal

Additionally, neoadjuvant Opdivo and chemotherapy showed improvements in the secondary efficacy endpoints of pathologic complete response (pCR; 25.3% vs. 4.7%) and major pathologic response (MPR; 35.4% vs 12.1%). 

The study is ongoing to assess its other secondary endpoint of overall survival (OS). 

Definitive surgery rates were 78% with the Opdivo-based regimen vs. 77% with chemotherapy and placebo, with complete resection achieved in 89% vs. 90% of patients, respectively.

In an exploratory analysis of the second BMS study, dubbed CheckMate-816, three cycles of neoadjuvant Opdivo with chemotherapy achieved a three-year event-free survival rate of 72%, compared with 47% in comparators who received chemotherapy alone.

Opdivo with chemotherapy reduced the risk of death by 63%. Three-year OS rates favored neoadjuvant Opdivo with chemotherapy over chemotherapy alone at 85% vs. 66%, respectively.

The PD-1 blocker also showed "promising" overall survival benefits and reduced the risk of death by 85% at three years, as opposed to 66% with chemotherapy alone. However, OS data from CheckMate-816 is still immature.

Price Action: BMY shares are down 0.17% at $57.28 on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!